Business
ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board
BURLINGAME, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO) a clinical-stage
About this update from Alx Oncology Holdings Inc.
[{"type":"text","content":"BURLINGAME, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the formation of the Company's Scientific Advisory Board (“SAB”) with three leading oncology experts. The SAB will provide valuable strategic and scientific counsel to ALX Oncology’s clinical programs related to its lead product candidate, ALX148.\n “We are honored to welcome these acclaimed experts in oncology to our scientific advisory board,” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. “These advisors will work closely with our leadership team and will be integral in helping to advance our clinical pipeline for ALX148 across multiple oncology indications.” “It is a privilege to work with a talented group of renowned oncology experts to assist ALX Oncology in developing ALX148, which has emerged as a next-generation checkpoint inhibitor designed to have high affinity for CD47 and to overcome the hematologic toxicity associated with other CD47 blocking approaches,” said Keith Flaherty, M.D., chair of ALX Oncology’s SAB. “ALX148 has the potential to make a significant impact on people who are fighting cancer.” The members of the ALX Oncology SAB include: Keith Flaherty, M.D. (Chair) - Dr. Flaherty is a Professor of Medicine at Harvard Medical School and Director of Clinical Research, at the Massachusetts General Hospital Cancer Center. He co-founded and served on the Board of Directors of Loxo Oncology until its acquisition by Eli Lilly and Company. He currently serves on the Board of Directors of Clovis Oncology and Checkmate Pharmaceuticals. Dr. Flaherty has been awarded numerous grants from the National Cancer Institute, including K23, RO1 and PO1 grants. He is an author of many research articles, abstracts and reviews in the peer-reviewed literature, including three first-author and three senior author New England Journal of Medicine papers. He serves as Editor-in-Chief for Clinical Cancer Research and on the Board of Directors of the American Association for Cancer Research. Dr. Flaherty holds a B.S. from Yale University and an M.D. from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital ...